National Comprehensive Cancer Network

Educational Events & Programs

NCCN Clinical Practice Guidelines in Oncology Symposium™ Non-Small Cell Lung Cancer

Friday, December 11, 2009 (Nashville, TN)

Register now to secure a seat at this symposium.

Program Overview:
Based on the deliberations of experts from 21 leading cancer centers, the NCCN Non-Small Cell Lung Cancer Guidelines provide sequential recommendations for the management of lung malignancies. This symposium will present these algorithms and focus on new approaches that have been incorporated into the guidelines, including the use of drugs, biologics, and diagnostics. The meeting format features case report presentations and audience feedback (via an audience response system) to highlight application of the guidelines in clinical practice. Participants are given the opportunity to comment on the guidelines with their developers and provide input for consideration in future updates.

Educational Objectives:
Following this program, participants should be able to:

• Describe the appropriate work-up for patients with non-small cell lung cancer;
• Describe the different surgical approaches to management based on site and stage at presentation and indications for surgery in non-small cell lung cancer;
• State the role of pre- and post-operative radiation in combination with chemotherapy in the management of non-small cell lung cancer;
• Describe the current status of neoadjuvant chemotherapy for Stage III non-small cell lung cancer;
• Outline the principles of surgical resection in non-small cell lung cancer;
• Identify the roles of new therapies in new management strategies for metastatic non-small cell lung cancer;
• Outline a multidisciplinary approach for the management of non-small cell lung cancer; and
• Describe the role of NCCN non-small cell lung cancer outcomes database in benchmarking quality of care.

Intended Audience:
This educational program is designed to meet the needs of oncologists, oncology nurses, pharmacists and other healthcare professionals who manage patients with cancer.

Tentative Agenda:

Accreditation:
Physicians
The National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

NCCN designates this educational activity for a maximum of 3.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurses
This activity is approved for 3.5 contact hours. National Comprehensive Cancer Network is an approved provider of continuing nursing education by PA State Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.

Approval as a provider refers to recognition of educational activities only and does not imply ANCC Commission on Accreditation or PA Nurses approval or endorsement of any product.

Kristina M. Gregory, RN, MSN, OCN, is our nurse planner for this educational activity.

Pharmacists

Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

This activity will be approved for continuing pharmacy education. A specific Universal Activity Number will be available prior to the activity.

This is a knowledge-based educational activity.

Faculty Disclosure
All faculty participating in NCCN continuing education activities are expected to disclose any conflict(s) of interest related to the content of their presentation(s) as defined by the ACCME’s and ANCC’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2 and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.

Program Location:
Sheraton Nashville Downtown Hotel
623 Union Street
Nashville, TN
(Directions)

Hosted By:
Vanderbilt-Ingram Cancer Center

Contributors:
Supported by educational grants from AstraZeneca and Abraxis BioScience; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb and ImClone Systems Incorporated; Eli Lilly and Company; Genentech BioOncology and OSI Oncology; Novartis Oncology; and sanofi-aventis U.S.

Registration Information:
Registration fees are:

If cancellation is necessary, please notify NCCN. A substitute attendee may be sent in your place. Registration fees are non-refundable.

Register now to secure a seat at this symposium.